Compare Eli Lilly And Co (LLY) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Eli Lilly And Co trades at $1,220.01 (market cap $1.08T), while Consumer Discretionary Select Sector SPDR Fund trades at $119.22. The key difference: Eli Lilly And Co pays a 0.57% dividend while Consumer Discretionary Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| LLY | XLY | |
|---|---|---|
Market Cap | $1.08T | — |
Sector | Health | — |
52-Week High | $1.24K | $124.52 |
52-Week Low | $639.43 | $105.64 |
Enterprise Value | $1.13T | — |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
XLY trades at $117.89, down 1.49% today, but maintains a bullish technical outlook with strong moving average support. The ETF benefits from positive analyst sentiment with a 100% buy rating and recent coverage highlighting its potential as a 'sleeper ETF' for Q3 2026. Technical indicators show overbought conditions with RSI readings above 70, but the overall trend remains positive with key support at $118.
The consumer discretionary sector faces headwinds from inflation pressures, but XLY's diversified exposure positions it for recovery. Near-term risks include consumer spending sensitivity to economic conditions, while the bullish analyst consensus and technical momentum suggest potential upside if market conditions stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
